novo nordisk's wegovy reduces cardiovascular risk more than lilly's tirzepatide A new round of data from Nordisk is once again pushing the conversation around obesity treatment into the spotlight. The company reported that some patients using a higher dose version of Wegovy Outperforms Tirzepatide in Reducing

GLP-1 and GLP-1 receptor agonists may represent novel drugs of therapeutic intervention with potential value, providing an alternative to the existing therapy for stroke

The medication provides a window of opportunity to establish new eating patterns, exercise habits, and metabolic health, but maintaining these changes often requires ongoing support and monitoring

Remarkably, RETA-induced protection extends to a lung cancer model with 50% reduced tumor engraftment, significantly delayed tumor onset, and mitigated tumor progression, with a 17-fold reduction in tumor volume compared to controls

I had about 15 pounds of menopausal weight that I simply could not lose on my own

The type and duration of antibiotic treatment can vary depending on the severity of the infection

Brutsaert DL (2003) Cardiac endothelial-myocardial signaling: its role incardiac growth, contractile performance, and rhythmicity